Global Stock News

  • February 27, 2026
Facebook-f X-twitter Linkedin-in Instagram

China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne

China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne

HANGZHOU and SHAOXING, China, Aug. 8, 2021 /PRNewswire/ — Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment…

Click here to view the original article.

Share this article

More News

Scroll to Top